08:00 - 12:00

LIVE SURGERY

AUDITORIUM

CHAIRS FROM AUDITORIUM:
Azzolini C., Binder S., De Molfetta V., Hassan T.,Loewenstein A., Romano M.

CHAIRS FORM ORs:
Florence: D'Amico D.J., Dhawahir-Scala F., Rezaei K., Steel D.
Kuwait City: Al Sabti K., Chow D.

SURGEONS:
Florence: Coppola M., Boscia F., Caporossi T., Mateo C., Mura M., Priglinger S., Pertile G., Tadayoni R., Parolini B., Mariotti C.
Tel Aviv: Barak A.
Kuwait City: Kadonosono K., EL Rayes E., Oshima Y.
Sulzbach: Szurman P.

08:00 - 09:00

VASCULAR RETINAL DISEASES

ROOM VERDE

CHAIRS: Arevalo F., Friberg T., Parravano M.

08:00 / Retinal vein occlusions: update on treatment options
Loewenstein A.
08:05 / Neuroprotection for Retinal Diseases
Kupperman B.
08:10 / Reversal of retinal ischemia after anti-VEGF therapy
Friberg T.
08:15 / Discussion
08:20 / Steroids in Retinal vein occlusions
De Smet M.
08:25 / Detection of retinal arterial microemboli after transcatheter aortic valve Implantation using SS-OCT-A
Zweifel S.
08:30 / Radial Peripapillary Capillay (RPC) plexus vascular study in patients affected by Arteritic Ischemic Optic Neuritis (AION): new OCT-A diagnostic signs
Pierro L.
08:35 / Discussion
08:40 / Sickle cells maculopathy: new findings
Viola F.
08:45 / Imaging and treatment of MacTel type 1
Nicolò M.
08:50 / New Findings in MacTel2.
Spaide R.F.
08:55 / Discussion

08:15 - 09:15

INHERITED RETINAL DISEASES

ROOM ONICE

CHAIRS: Da Cruz L., MacLaren R., Simonelli F., Sodi A.

08:15 / Retinal dystrophies diagnosis
Murro V.
08:20 / Cone degeneration in retinitis pigmentosa: mechanisms and therapeutic strategies
Falsini B.
08:25 / Precision Genome Surgery for Imprecise Medicine
Tsang S.
08:30 / Discussion
08:40 / RPE65-gene therapy: our experience
Simonelli F.
08:45 / Gene therapy for choroideremia
MacLaren R.
08:50 / Inhibition of Retinal Detachment-Induced Photoreceptor-Bipolar Cell Synaptic Disjunction with Rho Kinase Inhibitors: Potential Impact on Subretinal Surgery for Gene, Cell-Based, and Retinal Prosthesis Therapy
Zarbin M.
08:55 / Surgical issues in retinal dystrophies
Barca F.
09:00 / Discussion

09:00 - 10:00

VISION ACADEMY

ROOM VERDE

CHAIRS: Bandello F., Yoon Y.H.

09:00 / What Vision Academy is.
Loewenstein A.
09:05 / Management of submacular hemorrhage: Surgery
Figueroa M.
09:10 / Management of submacular hemorrhage: Anti-VEGF
Gale R.
09:15 / Management of submacular hemorrhage: Viewpoint from the VA
Cohen F.
09:20 / Treatment futility. Anti-VEGF treatment should be stopped when benefits are no longer expected. YES
Viola F.
09:25 / Treatment futility. Anti-VEGF treatment should be stopped when benefits are no longer expected. NO
Koh A.
09:30 / Treatment futility. Anti-VEGF treatment should be stopped when benefits are no longer expected. Viewpoint from the VA
Wong D.
09:35 / Optimal treatment regimen with anti-VEGF. Proactive
Wolf S.
09:40 / Optimal treatment regimen with anti-VEGF. Reactive
Bandello F.
09:45 / Optimal treatment regimen with anti-VEGF. Viewpoint from the VA
Lanzetta P.
09:50 / Discussion

09:15 - 10:00

LOW VISION

ROOM ONICE

CHAIRS: Huang S., Lam L., Richard G.

09:15 / Quality of life measurement in low vision patients
Virgili G.
09:20 / Reading with a central deep scotoma
Giacomelli G.
09:25 / Reading Aids for Central Low vision
Volpe R.
09:30 / Discussion
09:35 / Contrast sensitivity, light and low vision.
Farini A.
09:40 / Latest Advances in Technology in Vision Rehabilitation
Lam L.
09:45 / Limitations of artifical vision - Retinachip.
Richard G.
09:50 / Discussion

10:00 - 11:00

OMIKRON SYMPOSIUM: DIABETIC RETINOPATHY: EVIDENCES OF TOPICAL TREATMENT WITH NEUROPROTECTIVE AGENTS IN EYE DROPS

ROOM VERDE

CHAIRS: García-Arumí J., Loewenstein A., Sesti G.

10:00 / The pathogenesis of diabetic retinopathy
Sesti G.
10:15 / Neuroprotection: a link between glaucoma and CNS degenerative disease
Manni G.
10:30 / Neuroprotective effects of topical citicoline in models of retinal neurodegeneration
Bandello F.
10:45 / First results of RCT in diabetic retinopathy: the first topical treatment to slow down retinal damage
Parravano M.

10:00 - 11:00

BAYER SYMPOSIUM: AFLIBERCEPT IN MACULAR DISEASES: SHAPE THE DIFFERENCE

ROOM ONICE

10:00 / Recent advance in DME treatment
Midena E.
10:15 / Proactive dosing
Bandello F.
10:30 / Aflibercept durability in retina pathologies
Fornasari D.
10:45 / Discussion

10:00 - 11:00

OFFHEALTH SYMPOSIUM: MACULAR EDEMA: THE ROLE OF INFLAMMATION

ROOM 9

10:00 / Applications of OCT angiography in retinal edema
Introini U.
10:15 / Macular edema: a final common pathway of different retinal diseases
Bacherini D.
10:30 / Epidemiology and classification of uveitis and Clinical approach to a patient with uveitis
Miserocchi E.
10:45 / Discussion

10:00 - 11:00

HEIDELBERG ENGINEERING / VEDI VISION / FIMAS ENGINEERING SYMPOSIUM: WHAT’S NEW IN RETINAL IMAGING

ROOM 4

10:00 / OCT Angiography: Perls and pitfalls
Lupidi M.
10:10 / Swept source versus spectral domain OCT: which are the differences?
Staurenghi G.
10:20 / Looking at photoreceptors with a new confocal OCT software
Faraldi F.
10:30 / Radial Peripapillary plexus in diabetes
Midena E.
10:40 / Discussion

11:00 - 12:00

DIABETIC RETINOPATHY

ROOM VERDE

CHAIRS: Avitabile T., Bressler N., Bressler S., Virgili G.

11:00 / Two bangs for one buck: rates of diabetic retinopathy improvement and worsening while treating DME
Bressler S.
11:05 / Clinical highlights of DRCR Network treatment regimen for diabetic macular edema
Bressler N.
11:10 / Outcomes of anti-VEGF treatment for diabetic macular edema from clinical practice
Zweifel S.
11:15 / Fluocinolone acetonide: real-world data in DME
Lattanzio R.
11:20 / Discussion
11:25 / Vitreous hemorrhage in PDR: vitrectomy vs observation with/without anti-VEGF injections
Moisseiev J.
11:30 / Vitrectomy for DME unresponsive to pharmacologic therapy - is surgery beneficial?
Arevalo J.F.
11:35 / Tractional retinal detachment progression after preoperative anti-VEGF treatment: incidence and risk factors
Avitabile T.
11:40 / Pearls for management of complicated proliferative diabetic retinopathy
Mortada H.
11:45 / Survey
11:55 / Discussion

11:00 - 12:00

BASIC RESEARCH

ROOM ONICE

CHAIRS: Augustin A., Behar Cohen F., Eandi C., Siqueira R.

11:00 / Macular glial cells: Do we know everything?
Behar Cohen F.
11:05 / In vivo (animal and human) application of histopathology and molecular biology to nAMD, diabetic macular edema, retinal detachment and vitreoretinal interface disorders
Tosi G.M.
11:10 / The Role of Mitochondrial Genetics in Age Related Macular Degeneration
Kupperman B.
11:15 / Discussion
11:20 / On phagocytes and macular degeneration
Eandi C.
11:25 / Pharmacological Strategies for Improving RPE Transplant Survival in AMD Eyes
Zarbin M.
11:30 / Inflammatory retinal biomarkers in clinical models
Pilotto E.
11:35 / Discussion
11:40 / Role of inflammation in retinitis pigmentosa: inflammation markers in the aqueous humour
Bacherini D.
11:45 / The future of cell derived therapies for retinal degenerative disease
Binder S.
11:50 / Role of Muller cells in horizontal gliosis: how to close the large hole
Romano M.
11:55 / Discussion

12:00 - 13:00

3D RETINAWS

AUDITORIUM

PANELISTS: Bali E., Devin F., Eckardt C., Figueroa M., Garcia-Arum J., Mura M., Murray T.G., Rezaei K.

12:00 - 13:00

MACULOPATHIES: PACHYCHOROID

ROOM VERDE

CHAIRS: Behar Cohen F., Brucker A., Spaide R., Staurenghi G.

12:00 / Update on pachychoroid spectrum disease
Spaide R.F.
12:05 / Going deeper: advances in choroidal imaging
Staurenghi
12:10 / Pachychoroid neovasculopathy: aspect on OCT angiography
Savastano M.
12:15 / Early response to the treatment of CNV complicating CSC: a OCT-A study
Querques G.
12:20 / Discussion
12:25 / Risk factors for CSR.
Schwartz S.D.
12:30 / Multimodal imaging in the diagnosis and treatment of the Polypoidal Choroidal Vasculopathy
Ciardella A.
12:35 / The role of mineralocorticoid receptor antagonists in pachychoroid and choroidal neovascularization
Behar Cohen F.
12:40 / Photodynamic therapy for central serous chorioretinopathy
Eandi C.
12:45 / Discussion

12:00 - 13:00

PEDIATRIC RETINA ADVANCED COURSE

ROOM ONICE

CHAIRS: Capone A.J., Claes C., Saravia M., Trese M.

12:00 / Microvascular analysis of familiar exudative vitreoretinopathy using OCT-A
Capone A.J.
12:05 / FEVR surgical treatment
Barca F.
12:10 / Tips for the diagnostic and treatment of Stickler disease
Corcostegui B.
12:15 / Discussion
12:20 / Coats exudative retinal detachment treated with drainage of subretinal fluid, anti-VEGF and Wide-Field guided laser
Mastropasqua R.
12:25 / Pediatric macular holes.
Ferrone P.
12:30 / Long term outcome of combined vitrectomy and extensive ILM peeling in complicated pediatric rhegmatogenous retinal detachments
Mortada H.
12:35 / Discussion
12:40 / Ultra-wide field angiography in the management of Eales disease
Kumar P. (Floretina L. Barca Award 2017)
12:45 / Telemedicine for ROP management.
Trese M.
12:50 / Surgery in persistent fetal vasculature
Saravia M.
12:55 / Discussion

13:00 - 14:00

ALCON SYMPOSIUM: ADVANCED SOLUTION TO ENHANCE THE VITREORETINAL PROCEDURE

AUDITORIUM

MODERATOR: Boscia F.

13:00 / Introduction.
Boscia F.
13:02 / Upgrade vitreoretinal surgeries with the advanced capabilities of the surgical equipment
Claes C.
13:14 / Images modes customization to see more and do more - A milestone in 3D digital visualization
Figueroa M.
13:26 / DATAFUSION™ - Full integration of 3D Visualization in your surgical system
Mura M.
13:38 / Leverage a complete vitreoretinal portfolio at every step of the surgery
Boscia F.
13:50 / Discussion

13:00 - 14:00

NOVARTIS SYMPOSIUM: IT'S RIVAL TIME!

ROOM VERDE

13:00 / Introduction.
Bandello F.
13:05 / RIVAL trial: rationale and scientific relevance
Battaglia Parodi M.
13:14 / Images modes customization to see more and do more - A milestone in 3D digital visualization
Figueroa M.
13:20 / How evidences on efficacy change after RIVAL?
Vujosevic S.
13:35 / Individualized treatment for an optimal outcome
Nicolò M.
13:50 / Discussion

13:00 - 14:00

NIDEK SYMPOSIUM: NEW FRONTIERS IN RETINAL IMAGING: OCT ANGIOGRAPHY AND MULTIMODAL INTEGRATED EVALUATION

ROOM ONICE

MODERATOR: Schwartz S.D, Staurenghi G.

13:00 / The importance of multimodal imaging: the new SLO+OCT retinal platform
Staurenghi G.
13:10 / How OCT Angiography is changing retina practice: quantitative assessment of the retinal microvasculature
Schwartz, S.
13:20 / New approach in retinal imaging: novel diagnostic biomarkers using OCT-A and multimodal integrated evaluation
Bacherini D.
13:30 / From diagnosis to visual rehabilitation: new applications of MP-3 Microperimeter
De Rossi F.
13:40 / Discussion

13:00 - 14:00

BAUSCH+LOMB SYMPOSIUM: MICRONUTRIENTS AND BENEFITS OF SUPPLEMENTATION FOR REDUCING THE RISK OF RETINOPATHIES PROGRESSION

ROOM 9

MODERATOR: Querques G.

13:00 / Lecture: Nutritional supplement as therapeutic approach to Dry AMD
Arrigo A.
13:30 / Lecture: Role of micronutrients in the management of exudative maculopathy
Scuderi G.

13:00 - 14:00

GEUDER SYMPOSIUM: SHARING EXPERIENCES IN THE APPLICATION OF INNOVATIVE VITREORETINAL LIQUIDS

ROOM 4

CHAIR: Romano M.

13:00 / Introduction – Value of purity.
Romano M.
13:07 / Effects of a silicone oil solving agent on corneal endothelial cells
Spitzer M.
13:14 / Long-term experiences with heavier-than-water dyes in retinal surgery
Gerding H.
13:21 / Silicone oil with extended viscosity in routine surgery
Bertelli E.
13:28 / High viscosity silicone oil with extended viscosity in small gauge surgery
Chelini P.
13:35 / Experiences with heavy silicone oil in retinal surgery
Parolini B.
13:42 / Discussion

14:00 - 15:00

RETINAL DETACHMENT

AUDITORIUM

CHAIRS: Garcia Arumi J., Heimann H., Johnson M.

14:00 / 29 g directional spotlight - a new chandelier system
Eckardt C.
14:05 / ILM peeling for RD: should I do it?
Shah G.K.
14:10 / Retinal complications of long term silicone oil tamponades
Friberg T.
14:15 / Discussion
14:20 / Vitrectomy vs scleral buckling for primary retinal detachment: where are we today?
D'Amico D.J.
14:25 / Simplifying buckling surgery technique
Corcostegui B.
14:30 / Staining in PVR
Garcia-Arumi J.
14:35 / Discussion
14:40 / Only air tamponade in retinal detachment is possible?
Bali E.
14:45 / Repair of retinal detachment without vitrectomy adjuncts
Johnson M.
14:50 / Visual acuity recovery after retinal detachment: what can adaptive optics teach us?
Wolfensberger T.
14:55 / Discussion

15:00 - 15:55

WET AMD by ASRS

AUDITORIUM

CHAIRS: Ferrone P., Kim J.E., Shah G.

15:00 / Treatment regimens for neovascular AMD - where does the evidence point us?
Bressler S.
15:05 / Recent Updates from the AREDS2 Study
Kim J.E.
15:10 / Outcomes of anti-VEGF treatment for CNV in fellow eyes of previously treated patients with Wet AMD
Hassan T.
15:15 / Discussion
15:20 / Improving outcomes for patients with intermediate AMD: the role of genetic testing
Awh C.
14:25 / The Port Delivery System with ranibizumab for neovascular AMD: Phase 2 LADDER results and phase 3 ARCHWAY study design
Regillo C.D.
15:30 / Anti-VEGF gene therapy for AMD
Schwartz S.D.
15:35 / Challenges in the application of clinical trial results to clinical practice
Zarbin M.
15:40 / Discussion

15:55 - 16:15

FUTURE PERSPECTIVES IN OPHTHALMOLOGY

AUDITORIUM
Bausch+Lomb, Bayer, Dorc, Carl Zeiss

BAUSCH+LOMB:
Calvin W. Roberts (Senior Vice President, Chief Medical Officer)
BAYER:
Rafiq Hasan (Global Head of Ophthalmology)
DORC:
Thierry Leclerq (Chief Executive Officer) CARL ZEISS:
Thorsten Tritschler (Director Product Management Ophthalmic Surgery Systems, Medical Technology Business Group)

16:45 - 17:35

PEDIATRIC RETINA

AUDITORIUM

CHAIRS: Barca F., Campos E., Capone A., Trese M.

16:45 / Vitreoretinal interface in prematures
Claes C.
16:50 / Best approaches for pediatric retinal detachments
Ferrone P.
16:55 / Lensectomy when and how
Barca F.
17:00 / Discussion
17:05 / Management of stage 4 ROP in the anti-VEGF era
Capone A.J.
17:10 / ROP stage 5: do we still have to perform surgery?
Mura M.
17:15 / A developing regenerative therapeutic for retinal vascular disease
Trese M.
17:20 / Advanced treatment for complex retinoblastoma
Murray T.G.
17:30 / Discussion

17:35 - 18:20

INNOVATIONS

AUDITORIUM

CHAIRS: Da Cruz L., Van Meurs J.

17:35 / Gene therapy and CRISPR-mediated gene editing
Huang S.
17:40 / Eye606 non viral gene therapy for non infectious posterior uveitis: result from phase Ib/ IIa trial
Baggage R.
17:45 / Stem cell therapy for maculopathies
Schwartz S.D.
17:50 / Discussion
17:55 / LCA Therapy: From Fiction to Fact
B. Leroy
18:00 / New strategies of treatment of the Stargardt disease
Simonelli F.
18:05 / AR/VR (augmented/virtual reality) devices in patients with advanced AMD or other retinal diseases
Lam L.
18:10 / Discussion

18:20 - 19:00

IS IT TIME FOR THE AGE OF ROBOTS?

AUDITORIUM

CHAIRS: De Smet M., Schwartz S.D., Williams G.

18:20 / Robotic surgery as a delivery tool for novel retinal therapies
Da Cruz L.
18:25 / Robotic surgery - Promises, challenges and reality
De Smet M.
18:30 / Performance of robotics in macular pucker surgery - preliminary results of a randomized study
Faridpooya K.
18:35 / Discussion
18:40 / Comparison of robotic and manual surgery for internal limiting membrane peeling
Maberley D.
18:45 / A novel micro-surgical robot: preliminary experiences
Savastano A.
18:50 / Robotics - a means to automate surgery
Schwartz S.D.
18:55 / Discussion